Education

PharmD and PhD Medicinal Chemistry, University of California San Francisco

Research Interests

• cost-effectiveness modeling
• clinical, economic, and policy implications of pharmacogenomic-based drug therapies
• managed care decision-making

Courses Taught

• Pharm 520: Introduction to Pharmacoeconomics & Outcomes Research
• Pharm 534: Economic Evaluation in Health & Medicine
• Pharm 535/Hserv 584: Evaluating Cost & Outcomes in Health & Medicine
• Pharm 597: Graduate Seminar

Experience

Dr. Veenstra is an Associate Professor in the Pharmaceutical Outcomes Research and Policy Program in the Department of Pharmacy, and a member of the Institute for Public Health Genetics at the University of Washington.

He graduated from the University of California San Francisco, with doctoral degrees in clinical pharmacy and computational chemistry. He conducted his postdoctoral training in outcomes research with the University of Washington, including a one-year externship with Roche Global Pharmacoeconomics. Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of pharmacogenomic-based drug therapies. His major research projects include association studies of genetic variants with the outcomes of warfarin treatment, and cost effectiveness studies of genetic tests for warfarin, breast cancer, and lung cancer therapies.

Dr. Veenstra’s other major research interest is the development of disease simulation models for chronic diseases, particularly hepatitis B. He has worked extensively with the Academy of Managed Care Pharmacy to develop guidelines and train decision makers in the practical application of cost-effectiveness models. Dr. Veenstra is an author on over 60 scientific publications, including the journals JAMA, NEJM, and Science. Dr. Veenstra's methodological expertise is in cost-effectiveness modeling, including decision analysis, Markov modeling, and Monte Carlo simulation. Dr. Veenstra also has significant experience in developing disease simulation and cost-effectiveness models for chronic diseases, particularly hepatitis B.

As part of an ongoing series of Academy of Managed Care Pharmacy (AMCP) educational programs, Dr. Veenstra has worked extensively with formulary managers to assist them in evaluating cost-effectiveness models submitted by manufacturers to health care plans.

Activities

Dr. Veenstra is a member of the Institute for Public Health Genetics at UW, the International Society for Pharmacoeconomics and Outcomes Research, and the International Health Economics Association. Dr. Veenstra is a past recipient of the PhRMA Foundation Career Development Award in Pharmacoeconomics.

Publications

1. Meckley L, Gudgeon J, Anderson J, Williams M, Veenstra DL.  The cost-effectiveness of warfarin pharmacogenomic testing: A policy model, Pharmacoeconomics, in press.

2. David H. Salinger, Danny D. Shen, Kenneth Thummel, Ann Wittkowsky, Paolo Vicini, David L. Veenstra. Pharmacogenomic trial design: Clinial trial simulations of CYP2C9/VKORC1 testing for warfarin patients, Pharmacogen Genomics, in press.

3. Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol. 2009 May;24(5):786-91. Epub 2009 Apr 23.

4. Garrison Jr LP, Veenstra DL. The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer. Value Health. 2009 Jul 14. [Epub ahead of print]

5. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2009 Nov;135(11):1483-93.
Epub 2009 May 9.

6. Cheng MM, Lu B, Hu SS, Marelli C, Higashi MK, Patel PA, Li J,Veenstra DL.Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr. 2009 May-Jun;3(3):153-8. Epub 2009 Mar 31.

7. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data.  N Engl J Med. 2009 Feb 19;360(8):753-64.

8. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.
Pharmacoeconomics. 2008;26(11):937-49.

9. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb
Haemost. 2008 Aug;100(2):229-39.

10. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE,
Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.  Blood. 2008 Jun 5.
[Epub ahead of print]

11. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer. Value Health. 2008 Jul 18. [Epub ahead of print]

12. Veenstra DL, Spackman DE, DiBisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
 Aliment Pharmacol Ther. 2008 Jun;27(12):1240-52. Epub 2008 Mar 27.

13. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 2008;68(8):1105-13.

14. Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P, Milligan P, Grice G, Lenzini P, Rettie A, Aquilante C, Grosso L, Marsh S, Langaee T, Farnett L, Voora D, Veenstra D, Glynn R, Barrett A, McLeod
H.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clin Pharmacol Ther. 2008 Feb 27. [Epub ahead of print]

15. Garrison LP Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM,Veenstra DL.  A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications:
challenges and implications.  Drug Metab Rev. 2008;40(2):377-401.

16. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD,Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008 Feb 21.[Epub ahead of print]

17. Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-Negative Chronic Hepatitis B: Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan, Value In Health, 2008 Mar-Apr;11(2):131-8.

18. Karuna ST, Thirlby R, Biehl T, Veenstra D. Cost-effectiveness of laparoscopy versus laparotomy for initial surgical evaluation and treatment of potentially resectable hepatic colorectal metastases: a decision analysis. J Surg Oncol. 2008 Apr 1;97(5):396-403.

19. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K,Veenstra D, Williams MS, Watson MS; ACMG Working Group.
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008 Feb;10(2):139-50.

20. Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. Cytochrome P450 Enzyme Polymorphisms Frequency in Indigenous and Native American Populations: A Systematic Review, Community Genetics 2008;11(3):141-9. 

Associate Professor, Department of Pharmacy; Director, Graduate Studies and Postdoctoral Fellowship Programs in Pharmacoeconomics

veenstra@u.washington.edu